医药研发与生产外包服务

Search documents
睿智医药9月30日获融资买入916.92万元,融资余额2.03亿元
Xin Lang Cai Jing· 2025-10-09 01:31
截至9月20日,睿智医药股东户数4.47万,较上期减少5.99%;人均流通股10626股,较上期增加6.37%。 2025年1月-6月,睿智医药实现营业收入5.34亿元,同比增长14.75%;归母净利润2538.21万元,同比增 长140.35%。 分红方面,睿智医药A股上市后累计派现1.80亿元。近三年,累计派现0.00元。 机构持仓方面,截止2025年6月30日,睿智医药十大流通股东中,香港中央结算有限公司位居第四大流 通股东,持股2433.19万股,持股数量较上期不变。 责任编辑:小浪快报 9月30日,睿智医药跌0.78%,成交额1.19亿元。两融数据显示,当日睿智医药获融资买入额916.92万 元,融资偿还2227.71万元,融资净买入-1310.79万元。截至9月30日,睿智医药融资融券余额合计2.03 亿元。 融资方面,睿智医药当日融资买入916.92万元。当前融资余额2.03亿元,占流通市值的3.58%,融资余 额超过近一年70%分位水平,处于较高位。 融券方面,睿智医药9月30日融券偿还5300.00股,融券卖出0.00股,按当日收盘价计算,卖出金额0.00 元;融券余量4200.00股,融券 ...
睿智医药涨2.01%,成交额1.09亿元,主力资金净流出328.41万元
Xin Lang Zheng Quan· 2025-09-15 01:55
Company Overview - RuiZhi Pharmaceutical is located in Guangzhou, Guangdong Province, and was established on January 26, 2000. The company was listed on December 22, 2010. Its main business involves pharmaceutical research and production outsourcing services, micro-ecological nutrition, and micro-ecological medical services [1][2]. Financial Performance - For the first half of 2025, RuiZhi Pharmaceutical achieved operating revenue of 534 million yuan, representing a year-on-year growth of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, showing a significant increase of 140.35% year-on-year [2]. - Since its A-share listing, RuiZhi Pharmaceutical has distributed a total of 180 million yuan in cash dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 15, RuiZhi Pharmaceutical's stock price increased by 2.01%, reaching 13.67 yuan per share, with a total market capitalization of 6.807 billion yuan. The stock has risen by 112.93% year-to-date [1]. - The stock has experienced a slight decline of 0.58% over the past five trading days, but has increased by 1.79% over the past 20 days and by 24.16% over the past 60 days [1]. Shareholder Information - As of August 8, the number of shareholders for RuiZhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period. The average number of circulating shares per person increased by 23.28% to 9,038 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 24.33 million shares, with no change in the number of shares held compared to the previous period [3]. Market Position - RuiZhi Pharmaceutical operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing. The company is involved in various concept sectors, including Alzheimer's, biopharmaceuticals, peptide drugs, innovative drugs, and cancer treatment [2].